The estimated Net Worth of Edward P. Jordan is at least $451 dollars as of 2 March 2022. Mr Jordan owns over 12,500 units of Humanigen stock worth over $451 and over the last 11 years he sold HGEN stock worth over $0.
Mr has made over 2 trades of the Humanigen stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 12,500 units of HGEN stock worth $29,000 on 2 March 2022.
The largest trade he's ever made was exercising 14,700 units of Humanigen stock on 8 June 2021 worth over $141,855. On average, Mr trades about 2,267 units every 22 days since 2014. As of 2 March 2022 he still owns at least 12,500 units of Humanigen stock.
You can see the complete history of Mr Jordan stock trades at the bottom of the page.
Edward P. Jordan M.B.A. is the Chief Commercial Officer at Humanigen.
Mr A is 53, he's been the Chief Commercial Officer of Humanigen since . There are 4 older and 2 younger executives at Humanigen. The oldest executive at Humanigen, Inc. is Dr. Cameron Durrant M.B.A., M.D., MBA, 61, who is the Chairman & CEO.
Edward's mailing address filed with the SEC is C/O HUMANIGEN, INC., 830 MORRIS TURNPIKE, 4TH FLOOR, SHORT HILLS, NJ, 07078.
Over the last 5 years, insiders at Humanigen have traded over $2,588,252,690 worth of Humanigen stock and bought 2,107,496 units worth $5,417,461 . The most active insiders traders include Dale Cheval Holdings, Ltd.B..., Dale Black Horse Capital Ma... oraz Bay Ltd. Nomis. On average, Humanigen executives and independent directors trade stock every 34 days with the average trade being worth of $7,693. The most recent stock trade was executed by Dale Black Horse Capital Lp... on 18 October 2023, trading 386,350 units of HGEN stock currently worth $3,864.
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which has completed pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Humanigen executives and other stock owners filed with the SEC include: